Ustekinumab in Crohn's disease: evidence to date and place in therapy. (July 2016)

• Record Type: Journal Article
• Authors: Engel, Tal; Kopylov, Uri
• Is Part Of: Therapeutic advances in chronic disease. Volume 7:Number 4(2016:Jul.)
• Page Start: 208
• Page End: 214
• Publication Date: 2016-07
• Subjects: Crohn's disease -- interleukin 12/23p40 inhibitor -- ustekinumab; Chronic diseases -- Periodicals; Chronic diseases -- Treatment -- Periodicals; Chronic Disease -- Periodicals; Chronic Disease -- therapy -- Periodicals; 616.044
• DOI: 10.1177/2040622316653306
• Languages: English
• ISSNs: 2040-6223

Abstract

Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.